Current and historical daily PE Ratio for Australian Clinical Labs Ltd (
) from 2021 to Jun 06 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Australian Clinical Labs stock (ASX:ACL) PE ratio as of Jun 06 2024 is 29.74.
More Details
Australian Clinical Labs Ltd (ASX:ACL) PE Ratio (TTM) Chart
Australian Clinical Labs Ltd (ASX:ACL) PE Ratio (TTM) Historical Data
View and export this data going back to 2021. Start your Free Trial
Total 376
- 1
- 2
- 3
- 4
- 5
| Australian Clinical Labs PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-06 | 29.7 | 2024-04-05 | 33.9 |
| 2024-06-06 | 29.7 | 2024-04-04 | 34.3 |
| 2024-06-05 | 29.2 | 2024-04-03 | 34.7 |
| 2024-06-04 | 29.6 | 2024-04-02 | 34.9 |
| 2024-06-03 | 29.6 | 2024-04-01 | 34.9 |
| 2024-05-31 | 29.7 | 2024-03-29 | 34.9 |
| 2024-05-30 | 29.1 | 2024-03-28 | 34.9 |
| 2024-05-29 | 28.6 | 2024-03-27 | 35.3 |
| 2024-05-28 | 28.1 | 2024-03-26 | 35.1 |
| 2024-05-27 | 28.7 | 2024-03-25 | 34.2 |
| 2024-05-24 | 28.7 | 2024-03-22 | 34.5 |
| 2024-05-23 | 28.7 | 2024-03-21 | 34.5 |
| 2024-05-22 | 28.7 | 2024-03-20 | 34.3 |
| 2024-05-21 | 30.3 | 2024-03-19 | 33.8 |
| 2024-05-20 | 30.1 | 2024-03-18 | 33.1 |
| 2024-05-17 | 29.9 | 2024-03-15 | 33.3 |
| 2024-05-16 | 31.7 | 2024-03-14 | 32.9 |
| 2024-05-15 | 31.8 | 2024-03-13 | 33.5 |
| 2024-05-14 | 33.1 | 2024-03-12 | 33.0 |
| 2024-05-13 | 32.1 | 2024-03-11 | 34.4 |
| 2024-05-10 | 31.6 | 2024-03-08 | 34.3 |
| 2024-05-09 | 31.6 | 2024-03-07 | 33.3 |
| 2024-05-08 | 32.1 | 2024-03-06 | 33.3 |
| 2024-05-07 | 32.2 | 2024-03-05 | 33.4 |
| 2024-05-06 | 31.9 | 2024-03-04 | 32.5 |
| 2024-05-03 | 31.7 | 2024-03-01 | 31.7 |
| 2024-05-02 | 31.3 | 2024-02-29 | 31.0 |
| 2024-05-01 | 31.4 | 2024-02-28 | 31.6 |
| 2024-04-30 | 31.6 | 2024-02-27 | 33.9 |
| 2024-04-29 | 31.8 | 2024-02-26 | 36.2 |
| 2024-04-26 | 31.9 | 2024-02-23 | 36.0 |
| 2024-04-25 | 32.3 | 2024-02-22 | 36.1 |
| 2024-04-24 | 32.3 | 2024-02-21 | 34.9 |
| 2024-04-23 | 31.7 | 2024-02-20 | 37.0 |
| 2024-04-22 | 31.3 | 2024-02-19 | 37.9 |
| 2024-04-19 | 30.8 | 2024-02-16 | 38.4 |
| 2024-04-18 | 31.2 | 2024-02-15 | 39.0 |
| 2024-04-17 | 31.3 | 2024-02-14 | 39.0 |
| 2024-04-16 | 31.6 | 2024-02-13 | 39.2 |
| 2024-04-15 | 31.8 | 2024-02-12 | 38.6 |
| 2024-04-12 | 32.7 | 2024-02-09 | 38.3 |
| 2024-04-11 | 33.0 | 2024-02-08 | 37.8 |
| 2024-04-10 | 33.1 | 2024-02-07 | 37.1 |
| 2024-04-09 | 33.0 | 2024-02-06 | 37.4 |
| 2024-04-08 | 33.8 | 2024-02-05 | 38.3 |
Australian Clinical Labs Ltd (ASX:ACL) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Australian Clinical Labs Ltd
ISIN : AU0000148496
Description
Australian Clinical Labs, or ACL, is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers